{
    "label": "Is this request for initiation or continuation of therapy with Wegovy™ (semaglutide)?",
    "node_type": "fieldset",
    "children": [
        {
            "label": "Start of therapy",
            "outcome": "Authorization for Wegovy™ (semaglutide), is expected to be issued for 4 months",
            "node_type": "radio",
            "node_value": false,
            "children": [
                {
                    "label": "Treatment is being requested for appetite suppression or weight loss",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Patient is ≥ 12 years of age",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Used as an adjunct to lifestyle modification (e.g., dietary or caloric restriction, exercise, behavioral support, community-based program)",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "One of the following",
                    "node_type": "checkbox",
                    "node_value": false,
                    "children": [
                        {
                            "label": "Body Mass Index (BMI) ≥ 30 kg/m2 or for pediatric patients a BMI > 95th percentile",
                            "node_type": "checkbox",
                            "node_value": false
                        },
                        {
                            "label": "BMI ≥ 27 kg/m2 and patient has a weight-related comorbidity (e.g., dyslipidemia, hypertension, type 2 diabetes, sleep apnea)",
                            "node_type": "checkbox",
                            "node_value": false
                        }
                    ]
                }
            ]
        },
        {
            "label": "Continuation of therapy",
            "outcome": "Authorization for Wegovy™ (semaglutide), is expected to be issued for 12 months",
            "node_type": "radio",
            "node_value": false,
            "children": [
                {
                    "label": "Weight loss of ≥ 4% of baseline body weight for Wegovy",
                    "node_type": "checkbox",
                    "node_value": false
                },
                {
                    "label": "Continuation of lifestyle modification",
                    "node_type": "checkbox",
                    "node_value": false
                }
            ]
        }
    ]
}